Share
Overview
Dr (Prof) Vijay Agarwal is a medical oncologist at Apollo Hospitals, Bengaluru, with more than 25 years of medical and clinical experience.
He reviews your diagnosis and reports, explains the treatment options and helps you understand their benefits and limitations. Patients and families are encouraged to ask questions and take part in decisions.
Read 275+ patient reviews on GoogleBannerghatta Road profile
Clinical interests and expertise
- Medical treatment for solid tumours, such as breast, lung and bowel cancers
- Treatment planning and second opinions
- Chemotherapy and hormone therapy
- Immunotherapy, targeted therapy and antibody-drug conjugates
- Using tumour test results to guide treatment
Approach to care
Dr Agarwal considers the type and stage of your cancer, its test results, previous treatment, your general health and what matters to you. He aims to make the treatment plan clear and practical.
He works with other specialists when needed and reviews how treatment is affecting both the cancer and your daily life.
Qualifications and training
- PhD in Medical Sciences — Hull York Medical School (Universities of Hull and York), 2013. View PhD thesis
- Certificate of Completion of Training in Medical Oncology — General Medical Council (UK), 2012
- Postgraduate Diploma in Research Training — University of York (Hull York Medical School), 2011
- Postgraduate Certificate in Clinical Education — Newcastle University, 2008
- Membership of the Royal Colleges of Physicians (MRCP), UK, 2005
- MD in General Medicine — Kasturba Medical College, Mangalore (Manipal Academy of Higher Education), 2002
- MBBS — Jawaharlal Nehru Medical College, Belgaum (Karnatak University), 1999
Career and experience
- Since 2023: Professor and Lead Consultant, Medical Oncology, Apollo Hospitals, Bengaluru. Apollo Hospitals profile
- 2018–2023: Lead and Senior Consultant, Medical Oncology, Aster Hospitals, Bengaluru.
- 2015–2018: Senior Consultant, Medical Oncology, HealthCare Global, Bengaluru.
- 2013–2015: Consultant Medical Oncologist, Queen Elizabeth Hospital, University Hospitals Birmingham, UK.
- 2004–2013: Specialist oncology training, research and clinical practice in the United Kingdom.
Professional registration
- Karnataka Medical Council
- Registration no. 51540Verify registrationSearch 51540 and select Karnataka Medical Council.
- General Medical Council (UK)
- Reference no. 6046174Medical Oncology specialist registerView GMC record
- Dubai Health Authority
- Unique ID 92336231Consultant Medical OncologyView DHA record
Follow the regulator links for current registration and licensing status.
Clinical leadership and compassionate care
Dr (Prof) Vijay Agarwal was Clinical Lead of the Teenage and Young Adult Unit at University Hospitals Birmingham. During his leadership, the Teenage and Young Adult Service received the 2014 Kate Granger Award for Compassionate Care in the organisational or team category.
NHS England: 2014 award announcementPublications and presentations
Explore Dr Agarwal’s journal publications, conference abstracts and scientific talks. Each title links to a publication, programme or recording.
Journal publications
- Optimizing Premenopausal Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Management in India: Insights From Expert Consensus
Cureus. 2024;16(12):e76392.
- ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA)
BMC Cancer. 2023;23:737.
- Significance of emerging clinical oncology endpoints in support of overall survival
Indian Journal of Cancer. 2022;59(Supplement):S106–S118.
- Shared decision-making and medicolegal aspects: Delivering high-quality cancer care in India
Indian Journal of Palliative Care. 2020;26(4):405–410.
- Primary hepatic neuroendocrine tumor: A rare entity
Radiology Case Reports. 2020;15(11):2362–2366.
- The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma
Pathology & Oncology Research. 2020;26(2):985–995. First published online 2 April 2019.
- Is EGFR really a therapeutic target in head and neck cancers?
Journal of Surgical Oncology. 2019;119(6):685–686.
- Current Treatment Options for Human Epidermal Growth Factor Receptor 2-Directed Therapy in Metastatic Breast Cancer: An Indian Perspective
Indian Journal of Medical and Paediatric Oncology. 2018;39(3):368–379.
- Human epidermal growth factor receptor-2 expression in head and neck squamous cell carcinoma: A potential for targeted therapy?
Journal of Head & Neck Physicians and Surgeons. 2016;4:85–86.
- Genotype-Phenotype Analysis in an Indian Family Affected with Li-Fraumeni Syndrome-Role of Genetic Counselling
International Journal of Human Genetics. 2016;16(3–4):98–106.
- Clinical response to primary letrozole therapy in elderly patients with early breast cancer: Possible role for p53 as a biomarker
International Journal of Surgery. 2014;12(8):821–826.
- Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697
International Journal of Oncology. 2013;42(3):1088–1092.
- PTEN protein expression in malignant pleural mesothelioma
Tumour Biology. 2013;34(2):847–851.
- Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer
Journal of Proteomics. 2012;75(9):2745–2752.
- Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: A possible role for 14-3-3 theta/tau and tBID?
Journal of Proteomics. 2012;75(4):1276–1283.
- Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?
Cancer Treatment Reviews. 2011;37(7):533–542.
- Adjuvant! Online as a Decision-making Tool in Early Breast Cancer — a UK National Survey
Clinical Oncology. 2011;23(2):159–160.
- Urethral metastasis from non-seminomatous germ cell tumor: a case report
Journal of Medical Case Reports. 2011;5:12.
- Bevacizumab: Its Place in the Treatment of Advanced Non-small Cell Lung Cancer
Clinical Medicine: Therapeutics. 2009;1:715–725.
- Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report
Journal of Medical Case Reports. 2008;2:227.
Conference abstracts and posters
- Pre-treatment neutrophil lymphocyte ratio/platelet lymphocyte ratio as surrogate markers of survival in non-metastatic head and neck cancer patients: An observational study
ESMO Congress, Madrid, September 2017. Annals of Oncology. 2017;28(Suppl 5):v580–v581. Abstract 1651P.
Poster / abstract co-author
- Pre-chemotherapy nutritional status and chemotherapy response: An observational study
ESMO Congress, Madrid, September 2017. Annals of Oncology. 2017;28(Suppl 5):v543. Abstract 1539O.
Oral presentation; presenting author
- Stereotactic Robotic Radiosurgery for 1–3 Brain Metastases from Non–Small Cell Lung Cancer: A Single Institutional Experience from South India
International Journal of Radiation Oncology, Biology, Physics. 2017;98(1):238. Abstract 134.
Abstract co-author
- Effect of c-MET and MTOR inhibitors in malignant pleural mesothelioma (MPM) cells
EACR–AACR–SIC Special Conference, Florence, 20–23 June 2015. Abstract 626; proceedings page 30.
Abstract co-author
- Comparative proteomic approach for the identification of putative biomarkers of neoadjuvant chemotherapy resistance in luminal a breast molecular subtype
International Journal of Surgery. 2013;11(8):604.
Abstract co-author
- Proteomic identification of predictive biomarkers of neo-adjuvant chemotherapy resistance in breast cancer: A possible role of AkT-1, FAKY397, 14-3-3 theta/tau, tBID and BcL-XL?
European Journal of Surgical Oncology. 2013;39(11):S78.
Abstract co-author
- Assessment of neoadjuvant chemotherapy responses for locally advanced breast cancer patients: DCE-MRI vs resection histology
Association of Breast Surgery Conference, Manchester, 21–22 May 2013. European Journal of Surgical Oncology. 2013;39(5):493. Poster P113.
Abstract co-author
- Proteomic identification of putative biomarkers of breast neo-adjuvant chemotherapy resistance
Association of Breast Surgery Conference, Manchester, 21–22 May 2013. European Journal of Surgical Oncology. 2013;39(5):480–481. Poster P069.
Abstract co-author
- A comparative proteomic approach for identification of putative biomarkers of neoadjuvant chemotherapy resistance in breast cancer
ASCO Annual Meeting. Journal of Clinical Oncology. 2013;31(15 Suppl):e22123.
Abstract co-author
- Overcoming resistance to EGFR pathway inhibition in mesothelioma cells
International Mesothelioma Interest Group, Boston, 11–14 September 2012 · Poster P5.01.
Poster; first author
- Clinical response to primary Letrozole therapy in women over 70 years with early breast cancer: A retrospective study with a 5 year follow up
Association of Breast Surgery Conference, Bournemouth, May 2012. European Journal of Surgical Oncology. 2012;38(5):433.
Poster / abstract co-author
- Inhibition of EGFR, MTOR and COX2 pathways in mesothelioma cells
10th British Thoracic Oncology Group Conference, Dublin, January 2012. Lung Cancer. 2012;75(Suppl 1):S22. Abstract 66.
Poster / abstract co-author
- Inhibition of Epidermal Growth Factor Receptor in Malignant Pleural Mesothelioma
European Multidisciplinary Cancer Congress, Stockholm, September 2011. European Journal of Cancer. 2011;47:S141. Abstract 1158.
Poster / abstract co-author
- Growth Inhibition of Mammalian Target of Rapamycin (MTOR) in Malignant Pleural Mesothelioma
European Multidisciplinary Cancer Congress, Stockholm, September 2011. European Journal of Cancer. 2011;47:S140–S141. Abstract 1157.
Poster / abstract co-author
- Putative biomarkers in malignant pleural mesothelioma
Journal of Clinical Oncology. 2011;29(15 Suppl):e21008.
Conference abstract co-author
- Proteomic analysis of the mechanism of action of a COX2 Inhibitor (DuP-697) in mesothelioma
9th British Thoracic Oncology Group Conference, Dublin, January 2011. Lung Cancer. 2011;71(Suppl 1):S17. Abstract 49.
Poster / abstract co-author
- Expression of 5 & 12 lipoxygenase in malignant pleural mesothelioma
9th British Thoracic Oncology Group Conference, Dublin, January 2011. Lung Cancer. 2011;71(Suppl 1):S19. Abstract 55.
Poster / abstract co-author
- Expression of PTEN in malignant pleural mesothelioma
9th British Thoracic Oncology Group Conference, Dublin, January 2011. Lung Cancer. 2011;71(Suppl 1):S19–S20. Abstract 56.
Poster / abstract co-author
- Proteomic Identification of Predictive Biomarkers of Resistance to Neoadjuvant Chemotherapy in Luminal Breast Cancer: A Possible Role for 14–3-3 and BID?
San Antonio Breast Cancer Symposium, December 2011. Cancer Research. 2011;71(24 Suppl):P5-13-15.
Poster / abstract co-author
- Analysis of lipoxygenase pathways in malignant pleural mesothelioma
International Mesothelioma Interest Group, Kyoto, 2 September 2010 · Poster P03-4.
Poster co-author
- A prospective audit into the proportion of hospitalised oncology and haematology patients at risk of refeeding syndrome
Proceedings of the Nutrition Society. 2010;69(OCE2):E196.
Abstract co-author
- UK national survey on the use of Adjuvantonline as a decision-making tool in early breast cancer (www.adjuvantonline.com)
ECCO 15 / ESMO 34, Berlin, September 2009. European Journal of Cancer Supplements. 2009;7(2):318. Abstract 5194.
Poster / abstract co-author
- Prospective observational study of the proportion hospitalised cancer patients at risk of refeeding syndrome
ECCO 15 / ESMO 34, Berlin, September 2009. European Journal of Cancer Supplements. 2009;7(3):24. Abstract 58LBA.
Poster / abstract co-author
Scientific talks and debates
- Medical oncology perspective—role of re-differentiating agents and targeted therapy
Foundation for Head and Neck Oncology (FHNO), Bengaluru, 2025 · Thyroid cancer symposium.
Invited scientific talk
- Evolving role of immunotherapy in locally advanced head-and-neck squamous cell carcinoma
Foundation for Head and Neck Oncology (FHNO), Bengaluru, 8 November 2025.
Scientific talk
- Early Stage Lung Cancer — Adjuvant Chemotherapy
7th Lung Cancer Masterclass, Mumbai, 19 July 2024.
Scientific talk
- Role of Immunotherapy marker in developmental therapeutics
Best of ASCO, Bengaluru, 22 March 2024.
Scientific talk
- GI malignancies—updates from ASCO GI 2021 (1 July session)
Horizon Conference Management · Recorded session, 1 July 2021.
Scientific talk
- GI malignancies—updates from ASCO GI 2021 (2 July session)
Horizon Conference Management · Recorded session, 2 July 2021.
Scientific talk
- Integrating solid and liquid biopsy—Focus on Breast Cancer
ONCOVISION, Armed Forces Oncology Group Forum, Delhi, 23 February 2019.
Invited scientific talk
- NACT in HER2-positive breast cancer—Defining the best strategy
ONCOVISION, Armed Forces Oncology Group Forum, Delhi, 24 February 2019.
Invited scientific talk
- Immunotherapy for first-line advanced hepatocellular carcinoma—debate in favour
GI Oncology meeting, Ahmedabad, 21 September 2019.
Scientific debate—speaker in favour
- Role of hormonal therapy in advanced breast cancer
Bangalore Society of Obstetrics & Gynaecology, Bengaluru, 11 June 2017.
Scientific talk
- Population to Personalized Medicine
Association of Occupational Health Karnataka–HCG meeting, Bengaluru, 5 March 2017.
Scientific talk
- Role of targeted therapy in gynec oncology
Bangalore Society of Obstetrics & Gynaecology–HCG meeting, Bengaluru, 10 January 2016.
Scientific talk
Consultation locations
Call or WhatsApp CTI for help choosing a centre or arranging an appointment with Dr Agarwal.
Book through Apollo 24/7:
For Bannerghatta Road or Seshadripuram, select your preferred hospital on Apollo 24/7.
Jayanagar (tele-appointments only): Contact CTI to arrange
Treatment information
Cancer information
Explore our guides to cancer types and medicines for information about diagnosis, treatment and living with cancer.
In the news
Read selected articles, interviews and press coverage featuring Dr (Prof) Vijay Agarwal.
View news coverageCommon questions
Can I request a second opinion?
Yes. Bring your tissue test (pathology) reports, scan reports and images, any gene or other tumour test results, and previous treatment records. You do not need to repeat tests before the consultation unless advised.
How do I book an appointment?
You can book through the Apollo 24/7 links above or contact CTI for help. Jayanagar consultations are by tele-appointment only.
